Clinical trial · Interventional
Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation
Safety Study of Nature Killer Cells From Sibship to Treat the Recurrence of Hepatocellular Carcinoma After Liver Transplantation
NCT02399735CI-TRIAL-00023179unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to explore the safety of NK cells from Sibship in patients with recurrent hepatocellular carcinoma after liver transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Low Dose NK cells ×4 times | Biological | — | UNRESOLVED |
| Normal Dose NK cells ×4 times | Biological | — | UNRESOLVED |
| Normal Dose NK cells ×8 times | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Arm A
- description
- Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
- interventionNames
- Biological: Low Dose NK cells ×4 times
- type
- EXPERIMENTAL
- label
- Arm B
- description
- Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
- interventionNames
- Biological: Normal Dose NK cells ×4 times
- type
- EXPERIMENTAL
- label
- Arm C
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Proved hepatocellular carcinoma histologically after liver transplantation. * Confirmed recurrence of hepatocellular carcinoma by CT/MRI. * The same blood type relatives with blood transmitted diseases negative. * Written informed consent. Exclusion Criteria: * Autoimmune diseases require long-term of glucocorticoid. * Other candidates who are judged to be not applicable to this study by investigators. * Poor compliance.
References
Publications (1)
- DERIVEDYang F, Gong Y, Zheng X, Ni B, Lu J, Chen X, Cheng J, Li P, Du C, Chen Y, Zhang Y, Yi S, Wang G, Zhang Q, Yang Y, Chen W. NK cell infusion is well-tolerated and shows preliminary efficacy in patients with recurrent hepatocellular carcinoma post-liver transplantation : a phase I trial. J Transl Med. 2026 Jan 24;24(1):261. doi: 10.1186/s12967-026-07725-x. PMID 41580832